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Abstract 
Proteins of the bromodomain and extraterminal (BET) family, in particular bromodomain containing 
protein 4 (BRD4), are of significant interest as biological targets. BET proteins contain two separate 
bromodomains and existing inhibitors bind monovalently. Here we describe the discovery and 
characterisation of probe compound, biBET-6, capable of engaging both bromodomains simultaneously 
in a bivalent, in cis binding mode.  We provide evidence for this using a variety of biophysical and 
cellular experiments.  The bivalent binding results in very high cellular potency for BRD4 binding and 
pharmacological responses, for example, disruption of BRD4 / mediator complex subunit 1 foci with 
an EC50 of 100 pM.  These compounds will be of significant utility as BET / BRD4 chemical probes.  
This work illustrates a novel concept in ligand design, simultaneous targeting of two separate domains 
with a drug-like small molecule, providing precedent for a potentially more effective paradigm for 
developing ligands for other multi-domain proteins. 
  
Introduction 
The bromodomain (BRD) containing proteins are a family of proteins responsible for reading epigenetic 
acetylated lysine marks on histones and are rapidly emerging as a target class amenable to inhibition 
with small molecules1.  The bromodomain and extraterminal (BET) sub-family are perhaps the most 
widely explored of the class2.  Initially identified as a result of phenotypic screening for modulation of 
Apolipoprotein A1, subsequent target identification and compound optimisation has revealed multiple 
small molecule inhibitors of BET BRDs, which have progressed to preclinical and clinical 
evaluation3,4,5. 
The BET family consists of four proteins, termed BRD2, BRD3, BRD4 and BRDT6.  Each of these 
proteins contain two separate BRDs7.  Existing chemical probes, such as i-BET762 (1) (Fig. 1a), do not 
show selectivity for individual family members and are monovalent ligands, which bind monovalently 
to both BRDs within each protein with a 2:1 stoichiometry.  These chemical probes have been critical 
to elucidating underlying BET biology.  In the oncology field, the existence of tumour types driven by 
BRD4 fusion mutations5 and those in which critical oncogenes such as c-Myc are regulated by BRD48,9 
has led to great interest in BRD4 / BET inhibitors and a number are currently progressing in early 
clinical trials10. 
Here we describe our discovery of a new class of bivalent BET inhibitors, culminating in the chemical 
probe biBET-6.  We have shown, with a combination of techniques, that they act via an in cis binding 
mode, simultaneously engaging both BRDs in a single protein.  This binding mode results in 
significantly enhanced cellular potency and slow dissociation kinetics resulting in the most potent 
cellular probe for BET proteins described to date. 
 
Results 
Discovery of bivalent BET inhibitors 
As part of a programme to identify down regulators of the androgen receptor (AR), the development 
candidate AZD3514 was recently reported11,12.  AZD3514 displayed binding to the AR and cellular AR 
down regulation (DR) at similar and reasonably high concentrations.  We therefore embarked on a 
chemistry campaign focused on increasing potency, leading to the discovery of compounds such as 2, 
which possessed increased AR DR potency but showed a disconnect between binding and cellular 
potency values (Fig. 1a).  Moreover, it was revealed that these compounds also effected DR of the 
estrogen receptor-α (ER) at concentrations comparable to those seen for the AR, suggesting that there 
was indirect and unknown pharmacology driving both of these phenotypes. 
These findings led us to consider what the direct target of the compounds might be.  Comparison of 
these structures with known BET inhibitors led us to speculate that elements of our compounds might 
be capable of BRD binding and this might have been the cause of the observed pharmacology.  For 
instance, the chlorotriazole motif contained within the triazolopyridazine (TPDZ) of 2 could be 
overlayed with the methyltriazole of 1.  Alternatively, the piperazinone N-methyl and carbonyl groups 
could be overlayed with those of acetyl lysine.  Compound 2 was subsequently tested in a panel of BRD 
assays13, revealing activity against the BET family {pKd values of 7.2 against BRD4 isolated 
bromodomain 1 [BRD4(1)], 6.1 against bromodomain 2 [BRD4(2)], Fig. 1b}.  Further profiling in cells 
showed that 2 caused DR of c-Myc (Fig. 1c) and inhibition of tumour cell growth in a manner consistent 
with sensitivity to BRD4 inhibition, i.e. complete cell growth inhibition and a strong induction of 
apoptosis in BRD4 sensitive MM.1S, MOLP-8,  MV-4-11, and RS4;11 cells (pGI50 7.3, 7.2, 7.4 and 
6.8 respectively); partial growth inhibition without discernible apoptosis induction in less sensitive K-
562 (pGI50 6.0). 
We found that 2 also has weak activity for BRD4(1) and BRD4(2), but with values comparable to its 
AR binding and DR potencies.  It is interesting to note that an independent analysis has subsequently 
revealed that 2 has a similar pharmacological profile to BET inhibitors in cancer cell panels14,15.  The 
ability of BET inhibitors to effect inhibition of AR mediated signalling16 and ER DR17 has subsequently 
been reported. 
 
Induced dimerisation of BRD4(1) by X-ray crystallography 
Our structural hypotheses implied that either the TPDZ or the piperazinone group could engage the 
BET acetyl lysine pocket.  Solving the co-crystal structure of 2 in the presence of BRD4(1) (pdb code 
5AD2, Supplementary Table 1 and Supplementary Fig. 1) revealed a remarkable, compound-induced 
dimerisation of two BRD4(1) molecules within the crystal lattice, with 2 spanning both acetyl lysine 
binding sites (Fig. 2a).  The TPDZ group was observed to make hydrogen bonds with the side chain of 
Asn140 and a structural water molecule at the base of the pocket (Fig. 2b).  The piperidine ring 
projected over the WPF shelf (W81, P82, F83)3 and the aryl ring contacted the WPF shelf of the second 
bromodomain with the pendant piperazinone engaging the second binding site.  The piperazinone 
formed a strong H-bond with a structural water molecule and a weaker polar contact with the side chain 
of Asn140 (Fig. 2c). 
Optimisation of bivalent binding 
The dimeric X-ray structure was consistent with the structure activity relationships (SAR) we had 
observed in cellular assays with changes to both ends of the molecule that removed the observed 
interactions with the acetyl lysine pocket resulting in a loss of potency.  For example, replacement of 
the TPDZ chloro substituent (postulated to mimic the methyl of acetyl lysine) with an alternative methyl 
mimic, such as a trifluoromethyl group (3) retained activity; whereas deletion of the substituent (4) led 
to a loss of BRD4 affinity and cellular potency (Fig. 3a).  Moving the carbonyl substituent of the 
piperazinone to the 3-position (5), thereby disrupting the interaction with the critical Asn residue, led 
to loss of cellular potency but with retained BRD4(1) binding affinity. 
 
We reasoned that, in a bivalent complex, one of the BRD binding motifs may possess higher affinity 
than the other and pseudo-symmetrical compounds may have further increased potency.  The data for 
binding to BRD4(1) for 4 and 5 suggested that the TPDZ was the more potent warhead, given the greater 
loss of potency for 4 compared to 5.  Accordingly, we designed and synthesised compounds with a 
second TPDZ motif replacing the piperazinone of 3, resulting in pseudo-symmetrical compounds 6 and 
7 (Fig. 3b).  In this case, a methoxy substituted TPDZ was used as it was found that this substituent led 
to improved physical properties without a detriment to potency.  These compounds showed increased 
potency against BRD4(1), along with further increased potency against the tandem domain construct 
(pKd 11, Fig. 3c) and in cells (e.g. pEC50 9.2 and >9.3 for c-Myc DR for 6).  The compounds also 
retained a similar BRD selectivity profile to 3 (Supplementary Fig. 2).  These cellular potencies are, 
to the best of our knowledge, the highest reported to date for BRD4 inhibitors, being more than two 
orders of magnitude more potent than 1.  Rearrangement of the acetyl lysine mimic of the 
triazolopyridazine coupled with inversion of the stereocentre (8) led to significantly reduced BRD4 
activity and no detectable ER downregulation, providing an inactive control and further evidence that 
the observed pharmacology was BRD4 driven.  Compound 7 proved too insoluble (<1 µM) for further 
biophysical characterisation and so further studies focused on 6, which showed good in vitro ADME 
properties (Supplementary Table 2). 
In selectivity panels of 32 bromodomains13, 123 kinases and 147 secondary pharmacology assays, 6 
showed selectivity for the BET family compared with other BRDs (Supplementary Fig. 2), no 
detectable kinase activity at 1 μM (Supplementary Table 3) and only 10 of the other secondary 
pharmacology assays registered potencies below 10 μM (Supplementary Table 4) with the most potent 
being 5HT1B receptor (agonist EC50 0.93 μM, selectivity ratio of 1400 fold to BRD4 potency). 
The X-ray structure of 6 with BRD4(1) revealed a similar dimeric structure to that observed with 2 (Fig. 
3d, pdb code 5AD3, Supplementary Table 5, Supplementary Fig. 3).  The triazolopyridazine groups 
were seen to make differential interactions in the two bromodomains. One group made similar contacts 
with Asn140 and the structural waters as observed with 2, while in the other binding site, the hydrogen 
bonds to the waters were observed but that to Asn140 was not (Supplementary Fig. 4).  The latter is 
not as typically seen with triazolopyridazine structures and may not represent the mode of engagement 
that occurs in solution.  Indeed, a close analogue of 6 was observed to engage with Asn140 and the key 
structural water with both TPDZs under the same conditions (Supplementary Fig. 5). 
 
Determination of compound binding mode 
The enhanced potency of 6 and 7 against the tandem domain constructs and in cellular assays, led us to 
believe that the bivalent binding observed in the X-ray structure was relevant to their cellular 
mechanism of action.  Given the presence of two bromodomains in full-length BRD4, there are several 
possible binding modes for such bivalent compounds.  In one mode, the compounds may bind with 2:1 
stoichiometry with one compound occupying each BRD in the same way as observed for monovalent 
compounds such as 1 (Supplementary Fig. 6a).  This was considered unlikely to be the sole binding 
mode as it would not explain observed SAR or the difference in behavior relative to monovalent ligands 
such as 1.  Alternatively, the two warheads of a single molecule may bind to a bromodomain inducing 
an in cis complex (Supplementary Fig. 6b) or an in trans dimer (Supplementary Fig. 6c).  In the case 
of in trans binding, multiple possibilities exist with different combinations of each warhead binding to 
BD1 and BD2.  In addition, higher order multimeric species may form. 
A computational model of the full-length protein based on the structure of 2 using a homology model 
of BD2 and a simulated interdomain region showed that formation of an in cis complex was possible 
(Supplementary Fig. 6d) as well as an in trans dimer (Supplementary Fig. 6e) (see Online Methods 
section).  Under physiological conditions any one or more of these states may exist and the relative 
populations of each are likely to vary with both protein and compound concentration.  In particular, the 
2:1 complex is likely to dominate at very high concentrations as the protein becomes saturated with 
ligand. 
 
Binding of 1 and 6 to BRD4(1,2) tandem domain by NMR 
The first step in elucidating the binding mode of the compounds was to establish whether both 
bromodomains were engaged by the ligands in solution.  We recorded a series of two-dimensional 
transverse relaxation optimised 1H-15N heteronuclear single quantum coherence (TROSY HSQC) NMR 
spectra on tandem domain BRD4(1,2) (residues 44-460) in complex with monovalent 1 and bivalent 6 
at ligand to protein ratios of 1:1 and 2:1 (Fig. 4a).  BRD4(1,2) showed a chemical shift dispersion 
characteristic of a structured protein with an unstructured region (Supplementary Fig. 7a).  Tryptophan 
resonnances could be assigned by comaprison of the individual spectra for the isolated first (BD1) and 
second (BD2) bromodomains with that of the tandem domain (Supplementary Fig. 7b) allowing the 
W374 resonance in BD2 to be assigned and the remaining three tryptophan resonnances to be ascribed 
to BD1 (see Online Methods section).  Independent confirmation of resonances from BRD4(2) was 
obtained employing segmental isotope labelling of the C-terminal bromodomain of BRD4(1,2)18. 
Shifts in the signals for both domains were seen clearly in the presence of 1 in the slow-exchange regime 
typical for tight binding (Fig. 4a, Supplementary Fig. 7c).  Similarly, upon titration of 6, engagement 
of both domains simultaneously was observed.  Given the difference between the affinities of 6 
measured for BRD4(1) and BRD4(2), this observation is inconsistent with monovalent binding, where 
a greater proportion of engagement with BD1 would be expected.  In addition, binding of 6 significantly 
changed a number of other peaks in the spectrum, which were very different to those observed for 1.  
Together, these observations show that 6 binds to both BD1 and BD2 acetyl lysine pockets and suggest 
that its binding mode is different to that of 1 (for further discussion, see Supplementary Note 1). 
 
Characterisation of complexes of 1 and 6 by AUC and SAXS 
Analytical ultracentrifugation (AUC)19 for apo BRD4(1,2) showed a sedimentation coefficient (s20,W) 
of 2.46±0.05 S and an f/f0 ratio of 2.2, consistent with a dispersed monomer of highly extended 
conformation.  In the presence of 1, the sedimentation coefficient was very similar to that of apo 
BRD4(1,2) indicating no change in oligomeric state or gross conformation (Fig. 4b).  In the presence 
of 6, however, dramatic effects on the peak profiles and sedimentation coefficients were observed. At 
1:1, two peaks were observed; one with a similar sedimentation coefficient to apo BRD4(1,2) and a 
faster sedimenting species (coefficient 2.8 S).  To test whether these changes were due to 
conformational changes in the molecule, the data were analysed using a c(s,f/f0) model20.  The contour 
plot of the distribution of frictional ratios across the peaks of the 1:1 complex with 6 (Fig.  4c) showed 
that the frictional ratio of the species within the two peaks varied from ~2.2 for the first peak to ~1.4 
for the second, indicative of a conformational tightening of the molecule.  At 2:1 ligand:protein ratio, 
the same analysis revealed the formation of smaller populations of dimeric species (Supplementary 
Fig. 8).  These sedimentation analyses indicated that binding of 6 elicits a large conformational change 
in BRD4 resulting in a more compact shape and also suggested formation of a small proportion of 
dimeric species at higher ligand concentrations. These species likely represent in cis and in trans 
interactions between the BRDs induced directly by 6. 
Small angle X-ray scattering (SAXS)21 studies on apo BRD4(1,2) showed it to be largely monomeric 
at concentrations below 1 mg mL-1 (at increasing concentrations, the protein tended to aggregate in both 
presence and absence of compound and so the data were extrapolated to zero concentration for analysis) 
and was flexible in solution.  Ab initio and ensemble optimisation method (EOM) analysis22, suggested 
it was extended (Fig. 4d).  This changed very little upon addition of 1.  In the presence of 6, the protein 
became progressively and significantly more compact. The most compact complex was obtained at 2:1 
ligand:protein ratio, indicating the greatest population of in cis complex at this stoichiometry. 
We calculated distributions of interdomain distances (between Ile 110 in BD1 and Met 425 in BD2) 
from the 100 out of 10,000 theoretical models best fitting the experimental data (see Online Methods 
section).  In the apo protein, an average interdomain distance of 140±12 Å was observed (Fig. 4d) 
representing an absence of contacts between the two domains and the complex with 1 showed only 
slightly smaller distances.  In contrast, the complex with 6 had significantly shorter interdomain 
separations (average of 84±18 Å and 63±18 Å for the 1:1 and 2:1 complexes respectively).  The radii 
of gyration (Rg) showed a similar picture (Supplementary Table 6).  These data are strongly suggestive 
of a different binding mode of 6 compared to 1 and one in which a significant change in protein 
conformation is induced. 
The comparable interdomain distance in the BD1 dimeric crystal structure of 6 was 38 Å.  Hence, this 
is consistent with the formation of a complex with BD1 and BD2 in similar proximity in the SAXS 
experiment.  Since the Rg values for 6 are significantly lower than those for the apo protein and 
complexes with 1, it is reasonable to assume that the complex with 6 is mostly monomeric.  Taken 
together, this is highly suggestive of the formation of a significant population of an in cis complex.  
However, it must be noted that these data are extrapolated to infinite dilution and therefore may not be 
reflective of the binding mode under cellular conditions, under which higher order multimers may form. 
 
Cellular mode of action and pharmacology 
We developed bioluminescence resonance energy transfer (BRET) systems23 in HCT116 and HEK293 
cells to monitor interaction with chromatin using Halo-tagged histone H3 and a Nanoluciferase fusion 
protein with either BRD4(1) or full-length BRD4.  Compound 1 displaced both isolated BRD4(1) and 
full-length protein with the similar potency (Fig. 5a).  In contrast, 6 showed a remarkable (4 orders of 
magnitude) enhancement in potency for displacement of full-length BRD4 relative to BRD4(1) (pIC50 
9.6 and 5.6 respectively).  This potency increase provides evidence that the bivalent mechanism also 
operates in cells and is responsible for the cellular potency of 6.  Analogous experiments comparing 
full length wild-type BRD4 to the N433F point-mutant provided compelling evidence of the need to 
engage BD2 specifically to exert this effect (Fig. 5a). The mutant showed a similar chromatin 
displacement response to isolated BRD4(1) in these experiments and 6 had a comparable potency to 1 
(pIC50 6.6 and 6.8 respectively).  The binding of BRD4 to acetylated chromatin is believed to be 
dominated by BD1 interactions24 and the N433F mutation is known to provide a steric barrier to 
engagement of the BRD4(2) acetyl lysine pocket25 and so bivalent engagement of both acetyl lysine 
pockets by 6 is required to exert the increased potency. 
To detect if binding of 6 produced a conformational change within BRD4, a NanoBRET BRD4 
biosensor, was constructed consisting of the two tandem bromodomains, BD1 and BD2, expressed 
between HaloTag and NanoLuc fusions (Fig. 5b).  The signal in this conformational biosensor showed 
no change after treatment of 1 compared to basal levels.  Treatment with 6, however, showed a 
significant increase in signal at the concentration causing chromatin displacement.  The plateau of signal 
observed with 6 was highly suggestive of an in cis binding mechanism.  To study this further, a point 
mutant within BD1, N140F, was made within the biosensor.  This mutant biosensor demonstrated a 
similar basal level signal to the wild-type, no change in signal after treatment with 1 (Fig. 5b) and, 
strikingly, no response to 6.  Together these data support an in cis binding mechanism of 6 to both 
bromodomains within a single BRD4 protein. 
To analyze intracellular target engagement of the compound with BRD4, BRET was then monitored 
utilising a fluorescently labeled version of 1 in conjunction with Nanoluciferase fusion constructs of 
BRD4(1), full-length BRD4 and BRD4(N433F) competitively displaced with varying concentrations 
of test compound (Fig. 5c)26.  Again, 6 showed a remarkable difference in potency for displacement of 
tracer from full-length BRD4 relative to BRD4(1) and BRD4(N433F) (pIC50 9.0, 5.8 and 6.3 
respectively). The same was not observed for 1.  As anticipated, comparative experiments assessing 
intracellular target engagement (Supplementary Fig. 9) and acetylated histone displacement 
(Supplementary Fig. 10) for the other BET family members showed similar effects. 
Intracellular residence times of 1 and 6 were then determined, in which cells expressing Nanoluciferase 
fusions of BRD4 were incubated with the indicated single concentration, equivalent to the 
corresponding IC50 value, of compound for 3 hours [1 nM 6 used for full length BRD4 and 1 µM 6 used 
for BRD4(N433F) and BRD4(1)].  Following compound equilibration and multiple wash steps, 1 µM 
tracer was added to intact cells and the dissociation of 1 and 6 were measured26.  Compounds 1 and 6 
showed rapid dissociation from BRD4(1) and BRD4(N433F), whereas 6 showed slower displacement 
from full-length BRD4 (Fig. 5c).  Hence, the bivalent binding also leads to extended residence time 
compared to monovalent ligands. 
We next studied the disruption of BRD4 foci in native U2OS cells.  We observed bright BRD4 foci 
with immuno-staining using an anti-BRD4 antibody (Fig. 6a) and confirmed the specificity of the 
antibody by siRNA knockdown of BRD4.  Recent literature has described asymmetrical loading of 
BRD4 to super-enhancers (SEs), which are often associated with key genes that determine cell fate or 
those involved in oncogenesis27,28.  Histone H3K27 acetylation is a marker for active enhancers29.  
Mediator complex subunit 1 (MED1) and BRD4 have previously been shown high levels of binding to 
SEs and their levels are strongly correlated throughout the genome30.  Consistent with this, immuno-
costaining experiments showed that MED1 and H3K27Ac form foci in U2OS cells which overlap 
completely with those of BRD4. 
Treatment with 6 at 10 nM led to complete disruption of BRD4 and MED1 foci (Fig. 6b).  
Concentration-response data for 1 and 6 in this assay showed that 6 was a signficantly more potent 
inhibitor (pIC50 7.4 and 10 for 1 and 6 respectively, Supplementary Fig. 11).  There was no apparent 
change of H3K27Ac foci up to 24 h treatment with BRD4 inhibitors, whereas the disruption of BRD4 
and MED1 foci reached maxima within 3-4 h. 
The enhanced potency of 6 in BRD4 related assays translated into cancer cell killing activity  in a mixed 
panel of heamatoloical cell lines (Fig. 6c and Supplementary Fig. 12).  The bivalent binding of 6 
translated into highly potent cell killing activity in BRD4-dependent cell lines (pIC50 of 9.5 in both 
MV4.11 and MM.1S lines), representing a potency increase of approximately 3 orders of magnitude 
compared to 1.  Activity against BRD4 independent K-562 cells was weaker than for sensitive lines 
with both 1 and 6. Interestingly, the ALL cell line RS4-11 was quite sensitive to both BET inhibitors. 
However, monovalent 1 failed to achieve full inhibition, even at higher concentrations, whereas bivalent 
6 still achieveed near complete cell killing. This provides evidence of differentiated and possibly 
advantageous pharmacology from bivalent inhibition.  Changes in gene expression in response to 
treatment with 1 and 6 in MM.1S, MV-4-11 and K-562 cells revealed very similar expression profiles 
in response to both inhibitors (see Online Methods section) suggesting that enhanced cell killing effects 
of 6 are a direct consequence of the increased inhibitory potency as a result of bivalent inhibition rather 
than altered downstream gene expression. 
To further corroborate the extended intracellular BRD4 residence time observed for 6, we performed a 
drug washout using MM.1S cells and monitored c-Myc protein recovery overtime (Fig. 6d).  This 
clearly showed that 6 maintains knockdown of c-Myc protein levels upto 16 hours post washout.  In 
contrast, upon treatment with 1, c-Myc levels return to control levels within 1 hour of washout. 
 
Discussion 
This study revealed unique BET inhibitors (biBETs), which simultaneously engage two bromodomains 
leading to biochemical and cellular consequences beyond those shown with monovalent inhibitors.  
Enhanced cell potency correlated across a range of cell formats and end-points including AR and ERα 
immuno fluorescence in prostate and breast cancer cells respectively, transiently expressed engineered 
BRET protein-protein interaction systems and well characterised BRD4 related end-points such as c-
Myc DR in leukaemia cells (Supplementary Table 7).  The level of potency and selectivity achieved 
by 6, coupled with the comprehensive evidence for its enagement with BRD4 in cells make it the best 
cellular probe to date when judged against recently described criteria for chemical probes.31 
The results we have described provide compelling evidence for the bivalent mechanism.  The cellular 
SAR for the analogues is highly suggestive of 6 binding two BRDs simultaneously.  The X-ray crystal 
structures of the compounds in complex with an isolated BRD4(1) construct clearly demonstrate their 
ability to induce dimerisation of two BRDs.  The NMR experiments on tandem domain constructs 
showed that 6 engages both BRD4 BD1 and BD2 simultaneously in solution.  The AUC data 
demonstrated that binding of 6 leads to a protein of smaller radius than either the apo protein or that in 
complex with a monovalent ligand, suggesting that the bound complex in solution is mostly monomeric 
with respect to protein and that compound binding induces a more compact structure.  SAXS 
experiments showed a folding of the protein in response to ligand binding and demonstrate that the 
complex with 6 brings the two BRDs into close proximity, similar to that observed in the X-ray 
structures of BRD4(1) dimer.  Together, these data provide strong evidence for the formation of 
significant populations of in cis complex under the conditions studied.  The dramatic increase in potency 
observed in the cellular NanoBRET experiment for displacement of BRD4(1,2) from acetylated histone, 
relative to the BD1 construct alone, the analogous loss in BRD4(1,2) binding potency with the BRD4(2) 
binding site blocking mutation (N433F) and subsequent translation of this increased potency into BRD4 
driven pharmacology, along with increased BRET response for binding to doubly tagged BRD4(1,2) 
provide very strong evidence that 6 binds bivalently in cells with a significant population of an in cis 
complex forming. 
Cellular growth inhibition data showed that differential and potentially advantageous pharmacology 
arises from the bivalent binding mode in that complete inhibition of less sensitive cell lines was 
observed with 6, whereas monovalent ligands failed to achieve complete inhibition in these settings.  
This may be a result of bivalent binding per se or as a follow on consequence of the slow dissociation 
arising from the bivalent mechanism.  We anticipate that these effects will translate to in vivo settings 
although this would require optimization of pharmacokinetic profiles.  The pharmacology of bivalent 
inhibitors with optimized in vivo exposure are the subject of further publications32,33. 
The increased potency due to bivalent binding is presumably an avidity effect34.  Previous attempts to 
produce bivalent binders to BRDs35,36 and other proteins37 have been attempted in the past by linking 
two separate small molecule ligands with a flexible linker.  Compounds such as biBET-6 ,which 
partially fuse the two binding elements results in much more physical properties (6 has molecular weight 
of 531 and logD7.4 of 2.9), thus these compounds could conceivably be optimised to drugs.  Many 
proteins possess an arrangement of ordered functional domains joined by extended disordered regions.  
In particular, in the epigenetics field, protein-histone interactions achieve their affinity and specificity 
through the sum of weak interactions with different epigenetic marks38,39,40,41.  Development of bivalent 
ligands for these proteins in a manner analogous to that described here, could provide a means of 
developing superior chemical probes and, ultimately, drug molecules (Supplementary Fig. 14a) and 
could also provide a more effective means of targeting protein:protein complexes (Supplementary Fig. 
14b) (for further discussion, see Supplementary Note 2).  
From an initial hit molecule with an unknown target, we were able to follow cellular SAR to elucidate 
its molecular mechanism.  Further optimisation of the compounds based on this mechanistic hypothesis 
substantially improved potency by structure-based design, increasing the potency from micromolar to 
picomolar as a consequence of bivalent target engagement.  As a result, we have created biBET ligands 
which can simultaneously bind to two bromodomains.  It is also notable that these bivalent molecules 
deliver a very substantial increase in potency while maintaining acceptable size and physical properties.  
The resulting compound, biBET-6, is a very potent, selective inhibitors of BET BRDs and provides a 
chemical probe with distinct advantages over those previously described.  We anticipate that this will 
be invaluable in further elucidating the complex biology of BET proteins. 
 
Accession codes 
 
Pdb codes: 5ad2 for BRD4(1) in complex with 2, 5ad3 for BRD4(1) in complex with 6. 
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Figure Legends 
Fig. 1 – Discovery of a novel class of BRD inhibitor. a) Prototypic BET inhibitor i-BET762 (1) and 
potent AR down regulator 2. b) BRD selectivity data for 2 showing % binding at 10 µM, numbers 
above bars denote pKd values. c) Concentration response for c-Myc DR by Western blotting for 1 and 
2 in MM.1S cells (for further details see Online Methods section). 
 
Fig. 2 – X-ray crystal structure of 2 bound to BRD4(1) (pdb code 5AD2). a) Compound induced 
dimerisation. b) Interactions made by the TPDZ group in the acetyl lysine pocket. c) Interactions 
made by the piperazinone in the second acetyl lysine pocket.  Hydrogen bond distances (green dotted 
lines) are shown. 
 
Fig. 3 - Cellular SAR and optimisation of bivalent binding leading to 6. a) Deletions of BRD binding 
elements. b) Optimised bis-TPDZs 6 and 7 and an inactive control compound 8 modified to abrogate 
both binding events. c) Concentration response overlays for 6 in Bromoscan competition binding 
assays for BRD4(1) (circle), BRD4(2) (square) or BRD4(1,2) (triangle) d) X-ray structure of 
BRD4(1) dimer induced by 6 (pdb code 5AD3) (Supplementary Table 4). 
 
Fig. 4 – Biophysical characterisation of bivalent binding. a) 2D 1H-15N TROSY HSQC spectra 
recorded at 18.8 T of U-[2H,15N]-labeled BRD4(44-460)(grey) comapred to the spectra in the presence 
of 1 (red) and 6 (blue) at a ligand to protein ratio of 2:1. Boxed regions are shown expanded in 
Supplementary Fig. 7c and correspond to (i) a BD1 residue (unassigned) and (ii) the W374 indole 
amine of BD2. b) Sedimentation coefficient distributions for apo-BRD4(1-477) (grey) and in the 
presence of 1 (red) and 6 (blue at 1:1 and 2:1 ligand:protein ratios. c) Sedimentation coefficient 
distributions for 6 at 1:1 overlaid with the contour heat map of likely frictional ratios across the peaks. 
d) Ab initio shapes of the BRD4 constructs restored from the SAXS data for apo-BRD4 (grey) and 1:1 
complexes of 1 (red ) and 6 (blue); mean (± standard deviation). Further data on interdomain 
distances, Rg values derived from model fitting and χ2 values showing the goodness of the fit are 
given in Supplementary Table 6. 
 
Fig. 5 – Characterisation of binding mode in cells using nanoBRET systems. a) NanoBRET 
concentration response curves for displacement of BRD4(1), full-length BRD4 and BRD4(N433F) 
from labeled histone H3.3-Halo-tag by 1 and 6 comparing BRD4(1) to full length BRD4 in HCT116 
cells (top) and full length BRD4(1) to BRD4(N433F) in HEK293 cells (bottom), data are means of 3 
independent determinations and the error bars show the standard error in the means. b) NanoBRET 
system containing BRD4(1,2) with HaloTag BRD4(1) and NanoLuc BRD4(2) showing increased 
BRET response for WT BRD4(1,2) in the presence of 6, not observed for the N140F mutant or for 
binding of 1, data are means of 3 independent determinations and the error bars show the standard 
error in the means.  c) Intracellular NanoBRET target engagement using a fluorescent iBET-762-
based tracer.  Competitive displacement from full-length BRD4, BRD4(N433F) and BRD4 (1) in 
HeLa cells by 1 and 6. Residence time analysis of Compounds 1 and 6 on BRD4(1), full length BRD4 
and BRD4(N433F) in HeLa cells, data are means of 3 independent determinations and the error bars 
show the standard error in the means. 
 
Fig. 6 – Potency in cellular assays of BRD4 pharmacology. a) Formation of bright foci from super-
loading of BRD4 or Med1 to the super-enhancers (SE) marked by histone H3K27Ac in the chromatin 
regions. b) Disruption of BRD4 and Med1 foci by 6 (10 nM) and concentration response data for 1 
and 6. c) Growth inhibition data for 1 and 6 in BRD4 sensitive and insensitive lines.  Curves illustrate 
the responses in a sensitive (MM.1S) and less sensitive (RS411) line.  Full curves for the other tested 
lines are shown in Supplementary Fig. 12. d) c-Myc protein levels measured by Western blots for 1 
(1 μM) and 6 (50 nM) compared to DMSO control at 2, 4 and 16 hours post compound washout in 
MM.1S cells (for full length gels see Supplementary Fig. 13), error bars represent the standard 
deviations of triplicate determinations. 
Online Methods 
In vitro ADME data for 6 
Data were generated using standard protocols42,43. 
 
Protein preparation 
Plasmid constructs 
Variants of human BRD4 were generated by gene synthesis with an N-terminal hexahistidine tag and 
tobacco etch virus (TEV) protease site, and subcloned into pET28 vector for E.coli expression. 
BRD4(1,2) (residues 1-477), BRD4(1,2) (residues 44-460), BRD4(1) (residues 42-169), BRD4(2) 
(residues 333-460). 
Protein expression 
 In E. coli cells (BL21-Gold (DE3); Novagen), BRD4 proteins were induced using 0.1 mM isopropyl-
β-D-1-thiogalactopyranoside (IPTG) overnight at 18 °C.  
Protein purification 
Cells were resuspended in 50mM Tris pH 8.0, 300mM NaCl, 1mM  β-mercaptoethanol, 10mM 
Imidazole containing Complete protease inhibitor tablets (Roche) and  Benzonase nuclease 
(2.5u/ml).Resuspended cells were lysed using a Constant Systems cell disruptor at 25kpsi and clarified 
by centrifugation at 75,000 xg for 2 hours at 4ºC. 
BRD4 was purified from the supernatant by Nickel affinity chromatography, followed by cation 
exchange chromatography. Protein was further purified by size exclusion chromatography using a 
Superdex 75 10/300 GL column in 20mM Hepes pH 7.4, 100mM NaCl, 1mM Tris(2-carboxyethyl)
phosphine hydrochloride. 
For NMR spectroscopy and X-ray crystallography,the hexahistidine tag was removed from BRD4 by 
treatment with TEV protease after the Nickel affinity chromatography. 
Crystallisation & Structure of BRD4(1) in complex with 2 
E.coli expressed BRD4-(42-169) at a concentration of 10mg/ml was mixed with 2 to a final 
concentration of 200 µM, 2% DMSO and incubated on ice for 1 hour.  Note that due to limited solubility 
and DMSO tolerance, a molar excess of the compound concentration could not be attained.  Low 
volume sitting drop crystallisation was performed in MRC 2 well plates using a ratio of 2:1 protein : 
mother liquor and crystals formed in a condition containing 0.2M NaCl, 5.9% PEG 3350 (w/v), 10% 
ethylene glycol, 0.1M Hepes pH 7.4 at 4 °C.  Crystals were cryoprotected in mother liquor 
supplemented with a further 20% ethylene glycol.  Diffraction data was collected using a Rigaku FRE 
superbright generator with Osmic mirrors and a Saturn 944 CCD detector and processed using XDS44.  
Molecular replacement solution was determined with 2OSS.pdb using Phaser45.  The P212121 cell 
(α=β=γ=90°, a=41.618Å, b=59.615Å, c=106.773Å) has a dimer in the ASU.  Model building was 
performed using Coot46 and refined using Buster47.  2 could easily be modelled into the difference 
density using ligand restraints generated by Grade48.  It should be noted that the electron density for the 
ligand was of sufficient quality to enable it to be built in two alternate and equivalent conformations 
with a total final occupancy of 1.0. The statistics for the data collection and refined co-ordinates are 
given in (Supplementary Table 1).  The final model has been deposited in the protein databank under 
accession code 5ad2. 
Crystallisation & Structure of BRD4(1) in complex with 6 
E.coli expressed BRD4-(42-169) at a concentration of 10mg/ml was mixed with 6 to a final 
concentration of 200 µM, 2% DMSO and incubated on ice for 1 hour.  Note that due to limited solubility 
and DMSO tolerance, a molar excess of the compound concentration could not be attained.  Low 
volume sitting drop crystallisation was performed in MRC 2 well plates using a ratio of 2:1 protein : 
mother liquor and crystals formed in a condition containing 0.2M (NH4)2HPO4, 20% PEG 3350 (w/v) 
at 4 °C.  Crystals were cryoprotected in mother liquor supplemented with a further 20% ethylene glycol.  
Diffraction data was collected at beamline IMCA-CAT 17ID, Advanced Photon Source, Argonne 
National Laboratory, USA using a Dectris Pilatus 6M Pixel Array detector and processed using XDS.  
Molecular replacement solution was determined with 2OSS.pdb using Phaser.  The P212121 cell 
(α=β=γ=90°, a=109.64Å, b=41.826Å, c=59.591Å) has a dimer in the ASU.  Model building was 
performed using Coot and refined using Buster.  6 could easily be modelled into the difference density 
bound in a single orientation at occupancy of 1.0 using ligand restraints generated by Grade. The 
statistics for the data collection and refined co-ordinates are given in (Supplementary Table 5).  The 
final model has been deposited in the protein databank under accession code 5ad3. 
 
Measurement of endogenous ERα levels in the MCF-7 cell line 
Measurement of endogenous ERα levels in the MCF-7 cell line was carried out as previously 
described49. Briefly, the MCF-7 human breast ductal carcinoma cell line from the American 
Type Culture Collection (ATCC; HTB-22) was revived directly from a cryovial in phenol red 
free Dulbecco’s Modified Eagle’s medium (DMEM) containing 2 mM L-glutamine and 5% 
(v/v) charcoal/dextran treated foetal calf serum (FCS).  Cells were seeded into black, 
transparent bottomed, 384-well plates, at 1500 cells per well in a volume of 40 μl using a 
Multidrop Combi dispenser (Thermo Scientific).  Cell plates were incubated for 24 hrs at 37 
°C, 5% CO2.  An Echo 555 acoustic dispenser was used to dispense test compounds directly 
into cell plates producing a 12 point half-log duplicate concentration range (3.125 μM top 
concentration).  DMSO was dispensed in the maximum signal control wells to give a final 
concentration of 0.3% (v/v) and fulvestrant was dispensed in the minimum signal control wells 
to give a final concentration of 100 nM.  Cells were incubated for 18-24 hrs at 37 °C, 5% CO2 
and then fixed using a 3.7% (v/v) final formaldehyde concentration for 20 minutes.  The cells 
were washed three times with 250 μl phosphate buffered saline solution (PBS) using a BioTek 
ELx405 plate washer (BioTek Instruments, UK), and 50 l of PBS was added to all wells.  The 
PBS was aspirated and the cells permeabilised with 40 μl PBS containing 0.5% (v/v) Tween 
20 for 1 hr at room temperature.  The cells were then washed three times in 250 μl of PBS / 
0.05% (v/v) Tween 20 (PBST) using a BioTek EL406 plate washer.  20 μl was added per well 
of a 1:1000 dilution of ERα (Clone SP1 (epitope contained within a synthetic peptide derived 
from C-terminal of human estrogen receptor )) monoclonal rabbit antibody (Thermo Scientific, 
#RM-9101-S) in PBST  / 3% (w/v) bovine serum albumin (BSA) and the plates were incubated 
overnight at 4 °C.  The cells were washed three times in 250 μl of PBST and then incubated 
with 20 μl per well of a 1:500 dilution of goat anti-rabbit IgG Alexa Fluor 594 (Molecular 
Probes, Life Technologies, Paisley, UK) and a 1:5000 dilution of Hoechst (Molecular Probes) 
in PBST / 3% (w/v) BSA for 1 hr at room temperature.  The cells were washed three times in 
250 μl of PBST, 40 μl of PBS was then added per well, and the plates covered with a black 
plate seal.  Cell images were acquired using a Cellomics Arrayscan VTI HCS reader (Thermo 
Scientific) using a 10 x 0.3NA objective and applying the filters BGFR_386_23 and 
BGFR_549_15 to detect Hoechst and Alexa Fluor 594 signals.  Using the Compartmental 
Analysis v4 bio-application nuclear masks were generated from the Hoechst stained nuclei in 
channel 1 and a suitable threshold was applied in channel 2 to quantify ERα within the nuclear 
masks.  The mean total intensity was normalized for cell number giving the total intensity of 
ERα staining per cell. 
 
Measurement of endogenous AR levels in the LNCaP cell line 
(A) 96 well method using mouse anti-human AR monoclonal antibody (clone AR441).  
A modification of the previous immunofluorescence end point assay11 was used to measure levels of 
nuclear AR in the LNCaP prostate carcinoma cell line [LNCaP clone FGC (CRL-1740) obtained from 
the American Type Culture Collection (ATCC)].  LNCaP cells were cultured in Growth Medium 
[phenol red free Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen Code no. 11835-063), 
containing 2 mM L-Glutamine (Invitrogen Code no. 25030-024) and 1%(v/v) Penicillin/Streptomycin 
(10000 units/ml Penicillin and 10000 µg/mL of Streptomycin utilising penicillin G sodium salt) and 
streptomycin sulphate (prepared in normal saline, Invitrogen Code no. 15140122)  and 10%(v/v) foetal 
bovine serum (FBS)] in a 5% CO2 air incubator at 37oC.  Cells for assay were harvested from T175 
stock flasks by washing once in PBS (phosphate buffered saline, pH 7.4) (Invitrogen Code no. 14190-
094) and harvested using 5 mL of 1 x Trypsin / ethylaminediaminetetraacetic acid (EDTA) (10 x 
Trypsin-EDTA, 5.0 g/L Trypsin, 2.0 g/L of EDTA•4Na and 8.5 g/L of NaCl, without Phenol Red, 
Invitrogen Code no. 15400-054) diluted in PBS solution.  A 5 mLvolume of Assay Medium was then 
added to each flask [as above except that 5% (v/v) charcoal stripped FBS (HyClone Code no. 
SH30068.03) was included instead of 10% (v/v) FBS].  Cells were syringed at least twice using a sterile 
18G x 1.5” (1.2 x 40 mm) broad gauge needle and cell density was measured using a Countess 
automated cell counter (Life Technologies).  Cells were further diluted in Growth Medium plus 5% 
(v/v) charcoal stripped FBS and seeded at a density of 6.5x103 cells per well (in 90 µL) into transparent 
, black, tissue culture treated 96-well plates (Corning, # 3904).  Plates were incubated overnight at 37°C, 
5% CO2.  A 10x compound dose response plate with DMSO normalised to 3% (v/v) was generated in 
30 L of assay media using the Labcyte Echo 555 acoustic dispenser and a 10 L volume of diluted 
compound was then dosed to cells using a Thermo Scientific Matrix PlateMate to give a final 
concentration of 0.3% (v/v) DMSO and 8 or 12 point half-log singlicate concentration range (30 μM or 
3 μM top concentration).  DMSO was dispensed in the maximum signal control wells to give a final 
concentration of 0.3% (v/v) and either AZ13182659 or 6 was dispensed to generate a minimum signal 
to give a final concentration of 30µM or 3µM, respectively.  Plates were then further incubated for 20-
22 hours at 37°C, 5% CO2.  Plates were then fixed by the addition of 20 L of 10% (v/v) formaldehyde 
solution (in PBS) to each well [final formaldehyde concentration = 1.67%(v/v)] and left at room 
temperature for 10 min. The fixative solution was removed and cells were washed three times with 250 
L of PBS/0.05% (v/v) Tween 20 (PBST) using a Tecan PW96 plate washer (Tecan UK) and 50 l of 
PBS was added to all wells.  Immunostaining was performed at room temperature.  Cells were 
permeabilised by the addition of 35 L of PBS containing 0.5% (v/v) Tween 20 and incubated for 1 h 
at room temperature.  Permeabilisation solution was removed and cells were washed three times with 
250 L of PBST using an automated plate washer.  35 L of Blocking Solution [PBST containing 3% 
(w/v) Marvel dried skimmed milk (Nestle)] was added to each well and plates were incubated at room 
temperature for a minimum of 1 h.  Following removal of the Blocking Solution with a plate washer, 
35 L of mouse anti-human AR monoclonal antibody (clone AR441, DAKO, Code No. M3562), 
diluted 1:500 in Blocking Solution, was added to each well and incubated for 1 h.  
The primary antibody solution was removed from the wells followed by 3 x 100 L PBST washes using 
a plate washer.  Then 35 L of Alexa-Fluor 488 goat anti-mouse IgG secondary antibody (Invitrogen, 
Code No. A-11001), diluted 1:500 and Hoechst (Molecular Probes), diluted 1:5000 in Blocking 
Solution, was added to each well.  Henceforth, wherever possible, plates were protected from light 
exposure.  The plates were incubated for 1 h and then the secondary antibody solution was removed 
from the wells followed by 3 x 100 µL PBST washes using a plate washer.  Then 50 L of PBST was 
added to each well and plates were covered with a black plate seal.  Cell images were acquired using a 
Cellomics Cell Insight reader (Thermo Scientific) using a 10 x 0.3NA objective and applying the filters 
BGRFR_386_23 and BGRFR_485_20 to detect Hoechst and Alexa Fluor 488 signals.  Using the 
Compartmental Analysis v4 bio-application nuclear masks were generated from the Hoechst stained 
nuclei in channel 1 and a suitable threshold was applied in channel 2 to quantify AR within the nuclear 
masks.  The mean total intensity was normalized for cell number giving the total intensity of AR staining 
per cell.  Sample Images are detailed in Supplementary Fig. 15. 
 
(B) 384 well method using rabbit anti-human AR monoclonal antibody (PG-21) 
LNCaP cells were cultured as described above.  Cells were seeded into black, clear bottom, 384-well 
plates (Costar # 3712) at 3000 cells per well in a volume of 40 μl using a Multidrop Combi dispenser 
(Thermo Scientific) and then incubated overnight at 37°C, 5% CO2.  An Echo 555 acoustic dispenser 
was used to dispense test compounds directly into cell plates producing a 12 point half-log singlicate 
concentration range (30 μM or 3 μM top concentration).  Minimum and maximum controls were the 
same as for the 96 well assay.  Plates were then further incubated with compound for 18 hours at 37°C, 
5% CO2.  Cells were fixed by addition of 20µl/well of 12%(v/v) formaldehyde using a Thermo 
Scientific Matrix WellMate liquid handler (final formaldehyde concentration 4%(v/v)) and plates 
incubated at room temperature for 20 minutes.  The fixative solution was removed and cells were 
washed once with 250 L of PBS/0.05% (v/v) Tween 20 (PBST) using a using BioTek ELx405 plate 
washer (BioTek Instruments, UK).  Cells were then permeabilised by adding 20µl/well PBS containing 
0.1% Triton X-100 and incubated for 20 min at room temperature. Cells were washed once in PBS. 
Next, 20µl/well of PG-21 primary antibody (MilliPore #06-680) diluted 1:400 in antibody buffer 
(PBS/Tween 0.05% + 5% FCS), was added per well and plates incubated overnight at 4ºC. The 
following day, the plates were washed three times with PBS prior to addition of 20µl/well of secondary 
antibody (goat anti-rabbit AlexaFluor 488 diluted 1:500 in antibody buffer plus Hoechst nuclear stain 
diluted 1:5000).  Plates were protected from light and incubated for one hour at room temperature. The 
plates were then washed 3 times in PBS without a final aspiration step and covered with black plate 
seals. Cell images were acquired as above for the AR441 method.  Sample Images are detailed in 
Supplementary Fig. 16. 
 
Data analysis 
During the routine running of the biochemical and cellular cascade experimental data from each of the 
assays was exported into Genedata Screener® client graphing software (Genedata AG, Basel, 
Switzerland) to perform curve fitting analysis.  For the representative curves exemplified in the figures 
the data was plotted using Prism software (GraphPad Prism 6 Software, La Jolla, CA).  A nonlinear 
regression curve fit using four-parameters with variable slope was applied. 
IC50 values were determined by calculation of the concentration of test compound that was required to 
give a 50% reduction of the total measured effect corrected for background (average maximum control 
value minus the average minimum control value).  The quality of each assay was determined by analysis 
of the Z’ factor50. 
 
Measurement of AR binding 
Binding to AR was measured in LNCaP cellular extracts following an established method51. 
 
Bromoscan™ profiling 
Technology Overview - BROMOscan™ is a technology platform for identifying small molecule 
bromodomain inhibitors. Based on proven KINOMEscan™ technology, BROMOscan™ employs a 
proprietary ligand binding site-directed competition assay to quantitatively measure interactions 
between test compounds and bromodomains. This robust and reliable assay panel is suitable for high 
throughput screening and delivers quantitative ligand binding data to facilitate the identification and 
optimization of potent and selective small molecule bromodomain inhibitors. BROMOscan™ assays 
include trace bromodomain concentrations (<0.1 nM) and thereby report true thermodynamic inhibitor 
Kd values over a broad range of affinities (<0.1 nM to >10 µM). 
 
BROMOscan Primary Screen Protocol 
T7 phage strains displaying bromodomains were grown in parallel in 24-well blocks in an E. coli host 
derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen 
stock (multiplicity of infection = 0.4) and incubated with shaking at 32°C until lysis (90-150 minutes). 
The lysates were centrifuged (5,000 x g) and filtered (0.2μm) to remove cell debris. Streptavidin-coated 
magnetic beads were treated with biotinylated small molecule or acetylated peptide ligands for 30 
minutes at room temperature to generate affinity resins for bromodomain assays. The liganded beads 
were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1 % BSA, 0.05 
% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific phage binding. Binding 
reactions were assembled by combining bromodomains, liganded affinity beads, and test compounds in 
1x binding buffer (16 % SeaBlock, 0.5x PBS, 0.02%BSA, 0.04 % Tween 20, 0.004% Sodium azide, 
7.9 mM DTT). Test compounds were prepared as 1000X stocks in 100% DMSO and subsequently 
diluted 1:25 in monoethylene glycol (MEG). The compounds were then diluted directly into the assays 
such that the final concentrations of DMSO and MEG were 0.1% and 2.4%, respectively. In the primary 
screen compounds were tested at a final concentration of 3µM. All reactions were performed in 
polypropylene 384-well plates in a final volume of 0.02 ml. The assay plates were incubated at room 
temperature with shaking for 1 hour and the affinity beads were washed with PBST (1x PBS, 0.05% 
Tween 20). The beads were then re-suspended in elution buffer (1x PBS, 0.05% Tween 20, 2 μM non-
biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The 
bromodomain concentration in the eluates was measured by qPCR. 
 
BROMOscan Kd Protocol 
This was carried out as for the primary screen protocol above except for compound handling. An 11-
point 3-fold serial dilution of each test compound was prepared in 100% DMSO at 1000x final test 
concentration. This serial is then diluted to 100x in ethylene glycol and subsequently diluted to 1x in 
the assay (final DMSO concentration = 0.1%, Ethylene glycol concentration=0.9%). Kds were 
determined using a compound top concentration = 10 μM.  Binding constants (Kds) were calculated 
with a standard dose-response curve using the Hill equation: 
Response = Background + Signal - Background 
1 + (Kd Hill Slope / DoseHill Slope) 
The Hill Slope was set to -1. 
Curves were fitted using a non-linear least square fit with the Levenberg-Marquardt algorithm. 
 
Computational modelling 
Predicted structure models of the in cis and in trans complexes were built from the crystal structure of 
3. The BD2 domain was constructed through homology with the second BD1 domain of the crystal 
structure and the interdomain region was constructed using MOE homology model builder (Chemical 
Computing Group, Montreal, QC, Canada) with default parameters.  The relative positioning of the two 
pairs of domains for the in trans model was chosen so as to place the relevant termini approximately as 
far apart as they appear in the in cis model. 
 
NMR spectroscopy 
All NMR experiments were performed at 30 °C on a Bruker Avance III 800 MHz (18.8 T) spectrometer 
running TopSpin v3.2 and equipped with a 5mm z-gradient 1H/13C/15N TCI probe. The NMR sample 
used for the titrations contained 0.03 mM of 6 or 0.14 mM of 1 uniformly 2H,15N-labeled BRD4(44-
460) in 20 mM Na2HPO4, 2 mM TCEP (tris(2-carboxyethyl)phosphine), and 7%/93% D2O/H2O at pH 
6.7. Unlabelled compounds 1 and 6 were dissolved in DMSO to give a final concentration of 100 mM 
and were subsequently titrated into the protein sample to give ligand:protein stoichiometries of 0:1, 1:1 
and 2:1. Data sets were processed using the program nmrPipe52 and plotted using the Python program 
nmrGlue53. 
The distinction between the two BRDs was accomplished through comparisons with 2D TROSY HSQC 
spectra of isolated BRD4(1) and BRD4(2).  BD1 has three tryptophans in its sequence, whereas BD2 
contains one (W374), with indole nitrogen 1H resonances located between 9.6 and 10.5 ppm. Hence, by 
comparing the spectra of isolated BRD4(2) and BRD4(1,2) (Supplementary Fig. 7b), the signal for 
W374 was directly assigned. 
 
Analytical Ultracentrifugation 
Protein samples of BRD4(40-169) and BRD4(1-477) were characterised by sedimentation velocity 
analytical ultracentrifugation. Samples of protein of ~50 µM concnetration were initially analysed and 
buffer exchanged on a Superdex200 gel filtration column (GE), coupled to a Wyatt multi-angle light 
scattering detector (MALLS), a refractive index detector and UV detector,  which was equilibrated in 
10 mM Tris pH 7.4, 150mM NaCl. This performed buffer exchange and allowed analysis of sample 
heterogeneity and mass.  
All compounds were separately dissolved to a concentration of 1 mM in 100% DMSO. Protein 
samples were diluted in 10mM HEPES pH 7.4, 150mM NaCl to final concentrations of ~20 µM for 
BRD4 40-169, and 8 or 11 uM for BRD4(1-477). The final concentration of compounds was adjusted 
to compound:protein molar ratios of 2:1, 1:1, 0.5:1 and 0:1 by addition to the above protein samples.  
400 uL of each of the above samples were loaded into 2-sector epon centrepieces with sapphire glass 
and were centrifuged at 50,000 rpm in a Beckman XL-I ultracentrifuge at 20 °C collecting scans every 
1 minute until sedimentation of the protein was reached. Data was analysed using the sedimentation 
distribution modelling software Sedfit (REF), and used to calculate the frictional ratio (f/f0) from the  
frictional coefficient (f) and that of a sphere (f0). Analysis of  continuous c(s, f/f0) contour analysis was 
performed within Sedfit. 
 
Small angle X-ray scattering 
The synchrotron radiation X-ray scattering data from solutions of truncated BRD4 construct containing 
two bromodomains were collected in two experimental sessions at the beamline BM29 at the European 
Synchrotron Radiation Facility (ESRF, Grenoble)54. Using a Pilatus 1M detector at a sample to detector 
distance of 2.867 m and a wavelength of  = 0.09919 nm, the range of momentum transfer 
0.05 < s < 5.0 nm-1 was covered (s = 4 sin / , where 2 is the scattering angle). The apo protein 
solutions and those containing test compounds were measured at concentrations 1, 2, 5 and 10 mg/ml 
using a continuous flow cell capillary. To monitor for the radiation damage, 50 successive 0.2 s 
exposures of protein solutions were compared and frames with statistically significant changes were 
discarded. The data were normalized to the intensity of the transmitted beam and radially averaged; the 
scattering of the buffer was subtracted and the difference curves were scaled for protein concentration. 
The low angle data measured at lower protein concentrations were extrapolated to infinite dilution and 
merged with the highest concentration data to yield the final composite scattering curves. 
The forward scattering I(0), the radius of gyration Rg along with the distance distribution function of 
the particle p(r) and the maximum dimension Dmax were derived using the automated SAXS data 
analysis pipeline55. The p(r) functions were further recomputed manually with the program GNOM56. 
The molecular masses (MM) were evaluated by comparison of the forward scattering with that from a 
bovine serum albumin (MW = 66 kDa) reference solution. 
Ab initio shape models of the BRD4 constructs were generated using the bead modelling program 
DAMMIN57. This program represents the particle shape by an assembly of densely packed beads and 
employs simulated annealing to construct a compact interconnected model fitting the experimental data. 
Multiple runs were performed to generate 15-20 models. 
Using the Ensemble Optimization Method (EOM)22, a pool of 10 000 models comprising two rigid 
bromodomains (residues 42-168, PDB ID: 2oss and 349-458, PDB ID: 2yem) connected by a flexible 
linker, N-terminal tag and flexible N- and C-termini were generated. The scattering from each model 
from the pool was calculated with the program CRYSOL58. A subset of the pool was selected using a 
genetic algorithm such that the calculated averaged scattering of the selected models agreed with the 
experimental data. The Rg distributions of the selected ensembles were obtained by repeating the 
selection process multiple times. For the 100 models best fitting the experimental scattering from each 
construct the histograms of the distances between the centres of the two bromodomains were computed. 
For the top fitting model for each construct best the sedimentation coefficients were computed using 
WinHydroPro v.1.0059.  
1% DMSO was added to the inhibitor-containing solutions to improve their solubility. To verify that 
DMSO does not influence the results the apo protein was measured in 0%, 1% and 10% DMSO; after 
subtraction of the scattering of the appropriate DMSO-containing buffers it was found that DMSO 
addition does not affect the SAXS profile. 
All samples were measured at solute concentrations 1, 2, 5 and 10 mg/ml. A significant concentration 
dependence was observed for all samples indicating increased protein aggregation or oligomerisation 
with concentration. The magnitude of the concentration effect was different for the different 
constructs. For the apo protein data (Supplementary Fig. 17a) the effect was moderate indicating 
some degree of oligomerization (quantitatively, moderate dimerization). A similar albeit somewhat 
larger effect is observed in the presence of 1. For 6 (Supplementary Fig. 17b), the concentration 
effect was much more pronounced indicating formation of significant amounts of larger oligomers 
(tetra- octa- and even largrer). The data from all these concentration series were extrapolated to 
infinite dilution and the further analysis for all constructs was performed on the extrapolated data, 
which are expected to correspond to monomeric species (Supplementary Fig. 18). The p(r) function 
of the apo protein has a skewed shape typical for very elongated structures, with the maximum 
corresponding to the particle cross-section (about 4 nm).  From experimental data from the apo 
protein and from the mixtures with the ligands 1 and 6, each at three stoichiometries (ligand:protein, 
0.5:1, 1:1 and 2:1), extrapolated to infinite dilution, distance distribution functions were calculated 
using GNOM56. The overall structural parameters apparent molecular mass (MM) computed from 
forward scattering, the radius of gyration (Rg) and the maximum particle dimension (Dmax) were 
extracted from the extrapolated curves (Supplementary Table 8). 
A further and more detailed analysis of the results was performed using BRD4 sequence information. 
The available crystal structures of the bromodomains (PDB ID: 2oss and 2yem) correspond to 
residues 42-168 and 349-458 in the full-length construct, which consists of: His-tag (24 aa) + N-
terminus (41 aa), BD1 domain (127 aa), a 180 aa long inter-domain linker, domain BD2 (111 aa), C-
terminus (18 aa). 
According to the NORSnet prediction60, residues 1-60 and 168-351 are likely to be disordered.  
Therefore, it appeared likely that BRD4 is flexible in solution and appropriate analysis methods 
should be used to account for that. We employed the Ensemble Optimization Method (EOM), a 
technique where a large pool of randomized models is generated and sub-ensembles are selected in 
such a way that their mixtures fit the experimental data22.  10 000 models were generated keeping the 
crystal structures of the domains intact and randomizing the linkers. The properties of the system 
could be inferred from the analysis of the distributions of the overall parameters (e.g. Rg and 
interdomain distance) in the selected ensembles compared with the random pool.  
 
 
Bioluminescence Resonance Energy Transfer assay (BRET) NanoBRET assay 
Studies were performed using HEK293 or HCT116 cells.   HEK293 human embryonic kidney cell 
line or from the American Type Tissue Culture Collection (ATCC; CCL-247) were cultured in 
DMEM medium containing 2mM glutamine and 10% foetal calf serum. HCT 116 human colorectal 
carcinoma cells from the American Type Tissue Culture Collection (ATCC; CCL-1573) were 
cultured in McCoy’s 5A medium containing 2mM glutamine and 10% foetal calf serum. Cells (8 x 
105)  were seeded into wells of a 6-well culture plate (Corning) and allowed to attach for 6 hours. 
They were then co-transfected with Histone H3.3-Halotag (NM_002107) and either NanoLuc-BRD4 
full-length (1-1362) (060885), NanoLuc-BRD4 full-length N433F mutant, or  NanoLuc-N-terminal 
BRD4-BD1 (amino acids 44-168) expression vectors (Promega). For intramolecular biosensor 
experiments, cells were transfected with a Halotag-BRD4-BD1_BD2-NanoLuc (amino acids 44-460) 
fusion or a Halotag-BRD4-BD1(N140F)_BD2-NanoLuc mutant fusion expression vectors (Promega). 
Twenty hours post-transfection, cells were harvested and resupended in OptiMEM (Life 
Technologies) supplemented with  4% foetal calf serum at a density of 2 x 105 cells/ml  in the absence 
(control) or presence (experimental) of 100nM HaloTag NanoBRET 618 fluorescent ligand 
(Promega). Cells were then seeded into white, flat bottomed tissue culture-treated plates (Greiner), 90 
µl cell suspension per well, to which test compounds or vehicle (final DMSO concentration 0.1% 
(v/v)) were added as 10 fold solutions in complete media at various concentrations. Plates were 
incubated for 18 hours at 37oC in the presence of 5% CO2. NanoBRET Nano-Glo Substrate (Promega) 
was added to both control and experimental samples at a final concentration of 10 µM. Plates were 
read within 10 minutes using a CLARIOstar plate reader (BMG Labtech) equipped with a 450/80nm 
bandpass and 610nm longpass filter module. A corrected BRET ratio was calculated, defined as the 
ratio of the emission at 610nm/450nm for experimental samples (i.e. those treated with HaloTag 
NanoBRET 618 fluorescent ligand) subtracted by the emission at 610nm/450nm for control samples 
(i.e.those not treated with HaloTag NanoBRET 618 fluorescent ligand). BRET ratios were expressed 
as milliBRET units (mBU), where 1 mBU corresponds to the corrected BRET ratio multiplied by 
1000. 
 
Cell Transfection, Treatments, and Quantitative NanoBRET Target Engagement 
Measurements Under Equilibrium Conditions 
Target engagement at NanoLuc-BRD4 was performed as described previously26.  For determining 
unlabeled compound isotherms, the iBET-NCT tracer was added to the cells at a fixed concentration 
of 0.2 µM prior to test compound addition.  Serially-diluted test compounds were then added to the 
cells and allowed to equilibrate for 3 hr prior to BRET measurements.  To measure BRET, 
NanoBRET NanoGlo Substrate-(Promega) was added, and filtered luminescence was measure on a 
Promega Glomax Discover luminometer equipped with 450 nm BP filter (donor) and 610 nm LP filter 
(acceptor), using 0.5 s integration time.  Competitive displacement data were then graphed with 
GraphPad Prism software  using a 3-parameter curve fit with the following equation; 
Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))) 
Normalized data were generated by assigning 100% to the maximum of the 3-parameter curve fit and 
0% for the theoretical minimum value of the 3-parameter curve fit. 
 
 
Kinetic Analysis of Intracellular Residence Time at BRD4 via NanoBRET 
For direct analysis of relative compound dissociation rates via BRET, 2 x 106 cells transfected with 
NLuc-BRD4 constructs were processed as described previously26.  Briefly, transfected cells were first 
pre-equilibrated with test compound for 3 hr at 37°C/5% CO2.  Cells treated with compound were 
pelleted, washed once with PBS, and resuspended in 10 mL of Opti-MEM in the presence of 
NanoBRET NanoGlo Substrate and 1 µM iBET-NCT tracer immediately prior to BRET 
measurements.  BRET data were  normalized to 100% signal from the positive control (defined as the 
maximum BRET value observed from cells treated with 1uM iBET-NCT in the absence of unlabeled 
competing compound) and 0% signal (defined as the BRET value observed from cells treated with 1 
uM iBET-NCT + 10 µM unmodified 1). 
 
 
Cell lines  
All cell lines were originally purchased from ATCC or DSMZ, cultured following vendors’ 
instruction and authenticated using DNA fingerprinting short-tandem repeat (STR) assay and tested to 
be free of mycoplasma contamination. All revived cells were used within 15 passages and less than 6 
months.  
 
Immuno-fluorescent, foci assays for BRD4, MED1, and H3K27Ac 
U2OS cells were plated in 96-well plates at 16,000 cells/well. Cells were incubated at 37C in 5% 
CO2 overnight and then dosed with compounds at indicated concentrations for 4hr. DMSO was used 
as a max control. Cells were fixed by 4% formaldehyde at room temperature (RT) for 10 minutes and 
followed by 0.1% saponin permeabilization for another 10 minutes. Cells were co-stained by anti-
BRD4 antibody (1:25, Sigma Aldrich HPA015055-100UL) with either anti-MED1 antibody (1:50, 
Bethyl Laboratories A303-876A) or anti-H3K27Ac antibody (1:250, Diagenode C15200184) for 2 h 
at 37°C, washed with PBS for four times, and labelled by Alexa Fluor 488 anti-rabbit with either 
Alexa Fluor 594 anti-goat antibody or Alexa Fluor 594 anti-mouse antibody at 1:200 dilution (life 
Technology) for 1 h at RT. After washed with PBS twice, cells were stained with Hoeschst at 1:4000 
(life Technology, H21492) for 10 minute, washed twice with PBS and then subjected to image 
acquisition by ImageXpress MicroXL High Content Screening System (Molecular Devices). The data 
was analyzed by MetaXpress (Molecular Devices). IC50 was calculated using GraphPad Prism. 
 
c-Myc flow assay  
MM.1S cells were plated in 96-well plates at 200k cells/well and treated with serial concentrations of 
compound 1 h after plating and grown for 16 h at 37°C.   Cells were transferred into a 96-well V-
bottom plate and fixed sequentially with 2% paraformaldehyde for 10 min at 37°C followed with 90% 
cold methanol for 10min on ice.  Cells were washed and blocked in incubation buffer 
(PBS+0.5%BSA) for 10 min and incubated with anti-c-Myc primary antibody (1:200, Cell Signalling 
Technology #5605) at RT for 1 h. Cells were washed twice and then stained with Alexa 488 
conjugated anti-rabbit IgG (1:1000, Cell Signalling technology #4412) for 30 min at RT and washed 
again. The pellet was resuspended in incubation buffer and analyzed by flow cytometer (BD 
FACSCalibur) using the FL-1 detector. Data was analyzed using FlowJo software V7. Live cell 
population was selected by gating on FCS/SSC and Geo Mean fluorescence of FL-1 signal was used 
to calculate IC50s. 
 
 
Western blot experiments 
4 x 106 MM.1S cells were seeded in each well of the 6-well plates and treated with compounds at 
various concentrations for 4h. Crude lysate was prepared with 1xSDS lysis buffer (0.06 M Tris-HCl 
pH6.8, 1% SDS, and 10% glycerol). Samples with 20 µg of total protein were loaded and Western 
blots were run following typical procedures. Primary c-Myc antibody (CST #5605) was used at 
1:1000 dilution, GAPDH antibody (CST #5174) at 1:10,000 dilution, and secondary anti–rabbit HPR-
conjugated antibody (CST) at 1:10000 dilution. Protein level was visualized using the ImageQuant 
LAS4000. 
 
Cell growth inhibition and viability assays 
Optimal 384w seeding densities were pre-measured for linear growth over 72hr. 30ul cells/well were 
seeded in black, flat bottom 384w plates and treated with compounds for 72hr.  The viable cells were 
measured using Alamar Blue reagents following manufacture’s protocol (Invitrogen) and the % viable 
cells were calculated by comparing to no-drug controls. The percent net growth is calculated by 
normalising against the no-drug controls, and the GI50 value, the concentration that causes 50% net 
growth inhibition, was calculated using GraphPad Prism 6. 
Viability assay was performed following the same protocol as the growth inhibition assay but differed 
in data treatment.  Absolute number of remaining viable cells, instead of percent net growth, was 
determined after 72 hours of compound treatment.  Dose-response curves were plotted in GraphPad 
Prism and fitted using sigmoidal nonlinear regression to determine IC50 values. 
 
Gene expression analysis by RNA-seq 
To compare the genome-wide transcriptional consequences induced by the different BET inhibitors, 
we performed RNA-sequencing on hematologic cancer cell lines (K-562, MM.1S, MV-4-11, obtained 
from the American Type Culture Collection) after treatment with 1 (2 uM), 6 (0.05 uM) or DMSO 
control for 24 hours. Correlation analysis of the gene expression changes after inhibitor treatment 
revealed that the gene abundance differential strongly correlates between all compounds indicating 
that the transcription profile of each inhibitor is similar. 
After BET inhibitor (6 - 0.05 uM, 1 – 2 uM,) or DMSO vehicle treatment of cell lines (MV-4-11, 
MM.1S,  K-562) for 24 hours, RNA isolation, cDNA library generation, and sequencing to 12M reads 
on the Illumina HighSeq was carried out at Q2 Solutions (http://www.q2labsolutions.com/). Bcbio-
nextgen (https://github.com/chapmanb/bcbio-nextgen) was used to process FastQ files, perform 
quality control, alignment to genome build hg38 using HISAT261, and quantify transcription 
  
expression based on Ensembl annotation. DESeq262 version 1.12.1 was used to identify differentially 
expressed genes and calculate log10FoldChange values (Supplementary Fig. 19). 
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